Compositions and methods for treating diseases

Details Compositions and methods for treating diseases Compositions and methods for treating diseases

2008-10-24

2010-10-26

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S001100, C435S114000, C530S328000

Reexamination Certificate

active

07820626

ABSTRACT:
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.

REFERENCES:
patent: 5364884 (1994-11-01), Varma et al.
patent: 5428070 (1995-06-01), Cooke et al.
patent: 5504117 (1996-04-01), Gorfine
patent: 5873359 (1999-02-01), Zapol et al.
patent: 5919761 (1999-07-01), Wakefield et al.
patent: 6156975 (2000-12-01), Roos
patent: 6358536 (2002-03-01), Thomas
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6593292 (2003-07-01), Rothbard et al.
patent: 2002/0086829 (2002-07-01), Gefter
patent: 2002/0198136 (2002-12-01), Mak et al.
[Retreived from]: http://healthlibrary.epnet.com/GetContent.aspx?token=0a1af489-5b4c-4f2d-978e-3930be13b1f6&chunkiid=199430, 4 pages, 2010 [Retreived on Jan. 22, 2010].
[Retreived from]: http://www.medicineonline.com/articles/P/2/Pudendal-Neuralgia/Vulvodynia.html, 4 pages, 2010 [Retreived on Jan. 22, 2010].
[Retreived from]:http://www.rush.edu/rumc/page-1203344434680.html, 4 pages, 2010 [Retreived on Jan. 22, 2010].
Uemura 2002, Circ. J., 66, 1155-1160.
Nevin, et al., Pharmocology and Therapeutics, 2002, 95, 59-293.
Nathan et al., “Nitric oxide synthases: roles, tolls, and controls,” Cell (1994) 78:915-918.
Palmer, R. M., et al., “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,” Nature (1987) 327:524-526.
Yamada, M., et al., “Edothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment,” (2000) 20(4):709-17.
Harrison, David G., “Cellular and modecular mechanisms of endothelial cell dysfunction,” J. Clin. Invest. (1997) 100(9):2153-2157.
Wu, Guoyao and Morris, Sidney M., “Arginine metabolism: nitric oxide and beyond,” Biochem. J. (1998) 366:1-17.
Morris, Sidney M. and Billiar, Timothy R., “New insights into the regulation of inductible nitric oxide synthesis,” Am. J. Physiol. (1994) 266:E829-E839.
Dhanakoti, et al., “Renal arginine synthesis: studies in vitro and in vivo,” Am. J. Physiol. (1990) 253:E437-442.
Kown, M., et al., “L-arginine polymers inhibit the development of vein graft neointimal hyperplasia,” J. Thoras. Cardiovasc. Surg. (2001) 121(5):971-980.
Uemura, S., et al., “Rapid and efficient vascular transport of arginie polymers inhibits myointimal hyperplasia,” Circulation (2000) 102: 2629-2635.
Kown, Murray H., et al., “L-arginine polymer mediated inhibition of graft coronary artery disease after cardiac transplantation,” Transplantation (2001) 71(11):1542-1548.
Mitchell, D. J., “Polyarginine enters cells more efficiently than other polycationic homopolymers,” J. Peptide Res. (2000) 56:318-325.

Affiliated with

Also associated with

Rating

Compositions and methods for treating diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treating diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4233989